Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

REYKJAVIK,  ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.

GlobeNewsWire • Oct 28, 2026

New Strong Sell Stocks for October 21st

ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.

Zacks Investment Research • Oct 21, 2026

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio

GlobeNewsWire • Oct 20, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)

GlobeNewsWire • Oct 14, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership. Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time.

GlobeNewsWire • Oct 6, 2026

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira®

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites

GlobeNewsWire • Oct 5, 2026

LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday.

Benzinga • Sep 16, 2026

Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration.

GlobeNewsWire • Aug 31, 2026

Alvotech to present at upcoming investor conferences in September

REYKJAVIK,  ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:

GlobeNewsWire • Aug 27, 2026